Clinical effectiveness of long-term trimetazidine MB therapy in patients with cardio-respiratory disease (the results of an open, prospective multi-centre study)

Aim. To study the prevalence and clinical features of cardio-respiratory disease (CRD): coronary heart disease (CHD) + chronic obstructive pulmonary disease (COPD). To assess the long-term effectiveness of a myocardial cytoprotector, trimetazidine MB, as a part of complex therapy.

Material and methods. The retrospective analysis of 2446 medical histories assessed CRD prevalence and clinical features. The subjects were randomised into two groups: Group I (135 patients with CHD and severe COPD) and Group II (96 individuals with CHD and moderate COPD). Group I was administered trimetazidine MB (70 mg/d) for one year. Control assessments took place every three months.

Results. CRD was more prevalent in elderly CHD patients (56,7%). The combination of CHD and COPD was characterized by higher risk of Q-wave myocardial infarction (MI), unstable angina, complex arrhythmias, and early CHD progression, and increased time of silent myocardial ischemia. After one year of trimetazidine MB treatment, Group I demonstrated a significant decrease in angina episode incidence and silent myocardial ischemia time (p<0,05); in 64,4% of the patients, regression of cardiac symptoms and extrasystolia incidence were also observed.

Conclusion. Long-term trimetazidine MB therapy, as a part of complex treatment, normalised cardiovascular parameters, reduced complication risk, and improved prognosis in CRD patients, without any substantial adverse effects.

1. Оганов Р.Г., Масленникова Г.Я. Сердечно-сосудистые заболевания в Российской Федерации во второй половине XX столетия; тенденции, возможные причины, перспек-тивы. Кардиология 2000; 36(6): 4-6.

2. Чучалин А.Г. Хронические обструктивные болезни легких. Москва 1998; 11-26.

3. Rennard SL, Serby СW, Ghafoun M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996; 110(1): 62-70.

4. Sandford AJ, Weir TD, Pare P. Genetic risk factors. Eur Respir J 1997; 10:1380-91.

5. Палеев Н.Р., Черейская Н.К., Распопина Н.А. и др. Лечение артериальной гипертензии у больных с бронхи¬альной астмой. Клин Мед 1999; 77(12): 24-7.

6. Hida W, Tun Y, Kikuchi Y. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: recent advances in pathophysiology and management. Respiration 2002; 7: 3-13.

7. Плешаков А.В., Бакшеев В.И., Коломоец Н.М. и др. Частота встречаемости коморбидных состояний по данным многопрофильного амбулаторно-поликлинического учреждения. В кн. Российский национальный конгресс кардиологов. Повышение качества и доступности карди¬ологической помощи. Материалы конгресса 7-9 октября 2008 г. Москва. № 0718: 292-3.

8. Clauser P, Harpey C. Antioxidant properties of an antiischaemic agent: trimetazidine //Ed. I. Emerit. Antioxidants in therapy and preventive medicine. — New Yorc: Plenum Press 1999; 247¬50.

9. Григорьева Н.Ю. Влияние предуктала МВ на показатели ишемии и контрактильности миокарда, гемодинамику малого круга кровообращения у больных стабильной сте-нокардией, ассоциированной с хронической обструктивной болезнью легких. Нижегород мед ж 2003; 3-4: 8-12.

10. Guarnieri C, Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle. Cardiovasc Drugs Ther 1990; 4(5): 814-5.

11. Палеев Н.Р., Распопина Н.А., Федорова С.И. Существует ли “пульмогенная гипертензия”? Кардиология 2002; 42(6): 51-3.

12. Kantor PF, Lucien A, Kozak R. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long —chain 3-ketoacyl coenzyme A thiolase. Circulation 2000; 85(4): 580-8.

13. Диагностика и лечение стабильной стенокардии. Кардиоваск тер профил 2008;7(6): Приложение №4.

14. Morgan EE, Young ME, McElfresh TA, et al. Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Fundam Clin Pharmacol. 2006;20(5):503-5.

15. Tuunanen H, Engblom E, Naum A et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008; 118(12): 1250-8.

16. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 22(24): 2267¬74.

17. Chaloupka V. [Trimetazidine in the treatment of stable angina pectoris TRIADA-(trimetazidine in stable angina twice daily)]. Vnitr Lek 2006; 52(6): 609-14.

18. Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazidine in Angina Combination Therapy-the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005; 12(1): 35-42.

19. Kolbel F, Bada V. Trimetazidine in geriatric patients with stable angina pectoris: the tiger study. Int J Clin Pract 2003; 57(10): 867-70.

20. Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004; 20(9): 1447-54.

21. Marazzi G, Wajngarten M, Vitale C, et al. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. Int J Cardiol. 2006 Nov 27. [Epub ahead of print] PMID: 17134770.

22. Marazzi G, Gebara O, Vitale C, et al. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. Adv Ther 2009; 26(4): 455-61.

23. Gunes Y, Tuncer M, Guntekin U, et al. The effects of trimetazidine on p-wave duration and dispersion in heart failure patients. Pacing Clin Electrophysiol 2009; 32(2): 239-44.

24. Tallarico D, Rizzo V, Di Maio F, et al. Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. Angiology 2003; 54(2): 219-27.

25. Zhong P, Wang WY, Zhou XF, et al. [Effects of trimetazidine on myocardial metabolism evaluated by PET-CT in patients with ischemic cardiomyopathy] Zhonghua Xin Xue Guan Bing Za Zhi 2008; 36(1): 36-9.

26. Коломоец Н.М., Бакшеев В.И., Зарубина Е.Г., Увайсова К.У. Эффективность длительной терапии триметазиди- ном у больных с ишемической болезнью сердца в соче¬тании с хронической обструктивной болезнью легки. Кардиология 2008; 2: 47-51.

27. Лопатин Ю.М., Дронова Е.П. Клинико-фармако-экономические аспекты применения триметазидина модифицированного высвобождения у больных ишемической болезнью сердца, подвергнутых коронарному шунтированию. Кардиология 2009; 49(2): 15-21.

28. El-Kady T, El-Sabban K, Gabaly M, et al. Effects of trimetazidine on myocardial perfusion and the contractile respons of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005; 5: 271-8.

29. Di Napoly P, Giovanni P, Gaeta MA, et al. Trimetazidin and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d’Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol 2007; 50: 585-9.

30. Бакшеев В.И., Коломоец Н.М., Турсунова Г.Ф. Клиническое значение современных методик эхокардиографического исследования правых отделов сердца Клин мед 2006; 10: 16-23. http://www.cardiosite.ru/articles/article.asp?id=4190

31. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340(8828): 1111-5.

32. Global Initiative For Chronic Obstructive Lung Disease. Global Strategy For The Diagnosis, Management, And Prevention Of Chronic Obstructive Pulmonary Disease (2006).Copyright © 2006 MCR VISION, Inc. GOLD.WR.2006. www.goldcopd.org

33. Никитин Ю.П., Кузнецов А.А., Малютина С.К. и др. Прогностическое значение длительности и вариабельности интервалов Q—T и R—R в общей популяции Новосибирска. Кардиология 2002; 2: 76-83.

34. Макаров Л.М., Белозеров Ю.М., Жамлиханов Н.Х. Предикторы внезапной сердечной смерти при первичной легочной гипертензии по данным Холтеровского монито- рирования. Педиатрия 1994; 3: 34-6.

35. Heart rate variability. Standard of measurement, physiological, and clinical use. Task Force of European Society of Cardiology and The North American Society of Pacing and Electrophysiology. Eur Heart J 1996; 17: 354-81.